Home › Trials › NCT05882253
Clinical trial Recruiting at 1 site Interventional Men only

Improving early detection of prostate cancer using advanced MRI techniques

Official title: Validation, Calibration, and Translation of Restriction Spectrum Imaging Signal Maps to Enhance MRI Diagnostic Capabilities in Prostate Cancer

Run by University of California, San Diego · NCT05882253 · Data updated 2026-11-12

This study is testing a new MRI technique to see if it can help doctors find prostate cancer more accurately during biopsies.

Quick facts

Study typeInterventional
SexMen only
Enrollment225 (estimated)
SponsorUniversity of California, San Diego
Academic / other
Locations1 site (La Jolla, California)
StatusRecruiting
StartedDecember 4, 2023
Main results expectedDecember 2027
Study endsApril 2028
Registry record updatedJuly 17, 2025
Trial IDNCT05882253 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are men selected to undergo an MRI-fusion prostate needle biopsy who can provide informed consent.

Probably not a fit

Patients with a prior diagnosis of prostate cancer, metastatic disease, or those unable to undergo MRI will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI) in enhancing the accuracy of prostate cancer detection during MRI-guided prostate biopsies. It aims to validate the performance of RSI-MRI imaging biomarkers and calibrate their values across different MRI scanner manufacturers. Participants selected for an MRI-fusion prostate needle biopsy will be approached to join the trial, which is designed to provide insights into the clinical benefits of this advanced imaging technique.

Why it matters

Potential benefit: If successful, this study could lead to earlier and more accurate detection of clinically significant prostate cancer, improving patient outcomes.

How similar studies have gone: Other studies have shown promise in using advanced MRI techniques for cancer detection, suggesting a potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Selected to undergo an MRI-fusion prostate needle biopsy of the prostate.
* Able to provide informed consent

Exclusion Criteria:

* prior diagnosis of prostate cancer (Grade Group \>1)
* metastatic prostate cancer
* prior prostate cancer treatment
* contraindication to prostate biopsy (e.g., on anticoagulation that cannot be safely discontinued)
* inability to undergo MRI (e.g., too large to be accommodated in a scanner or with an implant incompatible with MRI).
* Bilateral hip replacement
* Unable to provide informed consent.

Where it's running

  • University of California, San Diego
    La Jolla, California, United States     Recruiting

Study contacts

  • Principal investigator: Michael A Liss, MD, PhD — University of California, San Diego
  • Study coordinator: Michael A Liss, MD, PhD
  • Email: liss@health.ucsd.edu
  • Phone: 858-249-1240

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464University of California, San Diego 1977
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.